Watz H, et al. - Whether alternative dosing strategies for roflumilast (ROF), an oral selective phosphodiesterase-4 inhibitor, would help its continuation as a therapy in COPD patients, was investigated herein. It was noted that 4 weeks' treatment with ROF 250 µg once daily (OD) before escalation to the approved maintenance dose of 500 µg OD led to reduced treatment discontinuation and improved tolerability in patients with severe COPD.